Apretude

Apretude is an injectable medication containing cabotegravir, used for HIV-1 pre-exposure prophylaxis (PrEP). This long-acting formulation is administered intramuscularly to help prevent HIV infection in at-risk individuals.

Apretude is primarily used for HIV-1 pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35 kg. It is designed for individuals at risk of HIV infection who may have difficulty adhering to daily oral medication regimens. The medication works by blocking the virus from replicating in the body, providing long-lasting protection.

Common effects of Apretude may include injection site reactions such as pain, tenderness, redness, and swelling. Some individuals may also experience headaches, fever, or fatigue. These effects are generally mild and temporary, but any persistent or severe symptoms should be discussed with a healthcare provider.

Apretude should be used with caution in individuals with a history of liver disease or hepatitis. It is important to inform your healthcare provider about all medical conditions and medications you are taking before starting Apretude. Regular monitoring and follow-up appointments are recommended to ensure the medication's effectiveness and safety.

Apretude may interact with certain medications, including those that induce or inhibit liver enzymes. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol consumption should be moderated, as it may affect the body's response to the medication.